Cancer center, The Chaim Sheba Medical Center, Ramat Gan, Affiliated with the Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel
Einat Shacham Shmueli , Morteza Raeisi , Benoist Chibaudel , Timothy S. Maughan , Jean-Yves Douillard , Eric Van Cutsem , Carsten Bokemeyer , Axel Grothey , Richard Adams , John Raymond Zalcberg , Takayuki Yoshino , Jean-Baptiste Bachet , Romain Cohen , Lama Sharara , Thierry Andre , Qian Shi , Aimery De Gramont
Background: Monoclonal antibodies (mab) targeting EGFR are recommended in L1 treatment (trt) for mCRC in patients (pts) with RAS wild-type (WT) tumor and primary left CRC. ARCAD database contains individual data of randomized trials that evaluated anti-EGFR mab plus chemotherapy (CT). In this analysis we aimed to evaluate anti-EGFR benefit in mCRC with lung mets, either as single site or multiple sites. Methods: Individual pts data from four trials (PRIME, CRYSTAL, COIN, OPUS) comparing CT +/- anti-EGFR were pooled. KRAS status was not required at inclusion to these studies. The primary endpoint, overall survival (OS), was estimated using Kaplan-Meier method, prognostic value of lung mets was evaluated by stratified Cox models in pts groups defined by KRAS status. The predictive value was evaluated by interaction test (Int) between trt and lung mets status in pts group defined by KRAS status and considered as significant with a P < 0.1. Results: 3681 pts with known KRAS status were included, 2171 WT and 1510 mutant (MT). Pts characteristics were well balanced. Significant median OS benefit of anti-EGFR was observed in the whole KRAS WT population and in the left colon and rectum subgroup but not in the right colon subgroup. In pts with KRAS WT single site mets, a non-significant benefit of anti-EGFR was observed only among pts without lung mets (N = 642). In pts with lung single site mets (N = 129), a significant benefit (P= 0.018) in the KRAS MT population (N = 55) was observed, but Int was non-significant (P =0.157). In pts with KRAS WT and multiple without lung mets sites (N = 673), no benefit of anti-EGFR was observed and Int was significant (P= 0.054). Pts with KRAS MT multiple sites with (N = 656) or without (N = 397) lung mets, had no benefit of anti-EGFR. The same findings were found in the left primary pts and in the two fluoropyrimidine backbone. PFS analyses confirm the OS results. Conclusions: In this ARCAD analysis pts with lung mets as a single site appear to benefit from anti-EGFR L1 therapy in case of KRAS MT. This unexpected result based on a limited sample size cannot be explained on the knowledge of anti-EGFR therapy. Furthermore, pts with multiple mets sites have a benefit of anti-EGFR therapy only in the presence of lung mets even in KRAS WT left primary tumor. These findings need further confirmation and may initiate the search for a specific molecular phenotype associated with lung mets in CRC pts.
Pts with lung mets as single site | Pts without lung mets as multiple sites | |||||
---|---|---|---|---|---|---|
N/Event | Median (95% CI) | HR (95% CI)P | N/Event | Median (95% CI) | HR (95% CI) P | |
KRAS WT – no EGFR-Ab | 35/29 | 20.9 (16.5,27.5) | Ref | 345/270 | 17.4 (15.8,19.9) | Ref |
KRAS WT – EGFR-Ab | 39/37 | 24.0 (14.4,39.7) | 0.75 (0.45,1.25) 0.265 | 328/253 | 18.3 (16.0,20.3) | 1.04 (0.87,1.23) 0.693 |
KRAS MT – no EGFR-Ab | 28/25 | 25.1 (14.9-34.3) | Ref | 183/149 | 16.8 (14.5,18.7) | Ref |
KRAS MT – EGFR-Ab | 27/18 | 40.1 (27.4-NA) | 0.42 (0.22,0.78) 0.006 | 214/184 | 12.6 (10.4,15.4) | 1.36 (1.10,1.69) 0.005 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Javier Soto Alsar
2024 ASCO Annual Meeting
First Author: Brian William Labadie
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Einat S Shmueli
2023 ASCO Annual Meeting
First Author: Vida Tajiknia